Last year a human trial involving administering gene therapy to Leber's congenital amaurosis (LCA) patients produced improvements in 12 children and young adults. The same researchers then conducted an animal study that found that a second injection into the previously untreated eye, was safe and effective with no signs of interference from immune reactions from the earlier injection.
Glaucoma remains the world's leading cause of irreversible blindness, but 50% of people who have this devastating disease don't know it,” said Dr Clive Midgal, president of the European Glaucoma Society.
The Congress of the French Ophthalmology Society, SFO, will take place at the Palais des Congres, 2 place de la Porte Maillot, Paris, France, 8-11 May 2010.
New research is emerging from the Vanderbilt Eye Institute that indicates the first sign of injury in glaucoma occurs in the brain.
A worldwide licensing deal has been made between NicOx, the French biotech business and Bausch & Lomb for the former's candidate glaucoma drug NCX 116.
Practices look to the future wit htechnology that integrates scheduling, electronic records and filing
Ophthalmic viscosurgical devices are designed to facilitate safety and control during phacoemulsification. But not all OVDs are created equal...
Reported highlights from sessions held during the 2009 XXVII ESCRS Congress in Barcelona, Spain.
Patients with neovascular AMD maintain visual acuity.
2009 heralded more interesting developments for ophthalmology. OTEurope asked some of Europe's leading key opinion leaders for their thoughts on the news and developments that generated most excitement or had most significance in the Cataract & Refractive sector
Sponsored Feature. Xalatan® is to become available across Europe in a newly designed bottle. So what does that mean and what lies behind that decision?
What should you be concentrating on with severe corneal burns?
A procedure that uses microwaves to alter corneal refraction may be alternative to LASIK in myopia patients
Optic design modification enhances vision performance without degrading contrast sensitivity
European School for Advanced Studies in Ophthalmology
Treating corneal neovascularization and the need for new and better treatments.
Greater, more consistent reductions seen throughout the day compared with brimonidine.
Nowadays ophthalmic surgeons have several treatment options for astigmatism. In Dr Detlef Holland's refractive department toric IOL and LASIK are the main options used.
Simultaneous IOPg, IOPcc measurements may provide significant data about patient groups.
Tips and techniquess for cataract and refractive success: The dry eye connection.
San Francisco?Anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration represent the most significant advancement in ophthalmology over the past decade, according to 52% of respondents to an online survey of members of the American Academy of Ophthalmology conducted in December.
Palomid 529 (P529) is to enter its Phase I trial in patients with AMD. A Phase I Open-Label Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single Intravitreal and Subconjunctival Doses of Palomid 529 in Patients with Advanced Neovascular Age-Related Macular Degeneration will according to Paloma Pharmaceuticals, be a dose-ranging study for safety but will also have an objective measure for efficacy.
Eye advance online publication 12 February 2010; doi: 10.1038/eye.2010.9
Eye advance online publication 12 February 2010; doi: 10.1038/eye.2010.3
VEGF Trap-Eye, the fully human, soluble VEGF receptor fusion protein that binds all forms of VEGF-A along with the related Placental Growth Factor (PIGF), has shown positive results in a Phase 2 study in patients with diabetic macular oedema (DME.
Researchers in the journal, Archives of Ophthalmology have indicated that results from a 4-year study of more than 21,000 Americans point to an association between glaucoma medications and a lower death rate.
LUVENIQ (LX211; oral voclosporin) has been filed for approval by the European Medicines Agency (EMA) and the US's Food and Drug Administration by Lux Biosciences. The drug is aimed at treatment of non-infectious uveitis for the intermediate or posterior segments of the eye.
Coherent is unique amongst laser manufacturers in the breadth of our excimer laser product portfolio and the depth of our experience in building products for both Laser-Assisted In Situ Keratomileusis (LASIK) and other refractive techniques.
A paper entitled A Placebo-Controlled Trial of Microplasmin Intravitreous Injection to Facilitate Posterior Vitreous Detachment Before Vitrectomy has been published online ahead of print in Ophthalmology.
Pfizer's CEO, Jeffrey Kindler has received the 2010 Catalyst Award, the Glaucoma Research Foundation's highest honour, acknowledging his role in sustaining innovative research and education.